Proxygen
- Company typePrivate
- Founded2020
- HeadquartersVienna, Austria
- Headcount51–100
- GTM typeB2B
- OfferingServices
Proxygen firmographics
Firmographics- Name
- Proxygen
- Legal name
- Proxygen GmbH
- Website
- https://proxygen.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Proxygen industry classification
Industry- Product category
- Targeted Protein Degradation Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Proxygen is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Proxygen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Pharmaceutical Partnerships and Licensing: Proxygen generates revenue through strategic research collaboration and license agreements with pharmaceutical companies. These arrangements provide upfront payments, research and development funding, success-based milestone payments tied to preclinical, clinical, regulatory, and commercial achievements, plus royalty payments on net sales of developed products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Proxygen product offering
Product offeringCore offering
Proxygen develops molecular glue degraders and induced proximity therapeutics using a proprietary, ligase-agnostic discovery platform that integrates genomics, proteomics, and biochemistry to systematically identify degraders against previously undruggable proteins. Its pipeline includes a first-in-class oral p300 glue degrader for transcription-driven cancers and a brain-penetrant CDK12/Cyclin K degrader for HER2-driven cancers with CNS involvement, advanced through strategic research collaborations and license agreements with global pharmaceutical companies.
Product overview
Proxygen is a Vienna-based biotechnology company pioneering the discovery and development of molecular glue degraders and induced proximity therapeutics. The company's portfolio centers on two lead clinical-stage programs: the p300 molecular glue degrader for transcription-driven cancers and the CDK12 (Cyclin K) brain-penetrant degrader for HER2-driven cancers with CNS involvement. These programs are powered by Proxygen's proprietary discovery platform that enables systematic identification of glue degraders against previously undruggable targets. The company also maintains partnered programs with MSD (Merck & Co) and is expanding its platform beyond degradation into broader induced proximity mechanisms.
Differentiator
Problem solved
Functional benefit
Products and services
- p300 Molecular Glue Degrader Program First-in-class oral molecular glue degrader targeting the transcriptional co-activator p300 with sub-nanomolar potency and differentiated covalent glue pharmacology, designed to address transcription-driven cancers including prostate, lung, and bladder cancer through catalytic degradation and PK/PD decoupling.
- CDK12 Molecular Glue Degrader Program First-in-class brain-penetrant molecular glue degrader that inactivates CDK12 via Cyclin K degradation, with high selectivity across the CDK family, designed to address HER2-driven cancers with CNS metastases and transcriptional dependencies in HER2-driven cancers.
- Molecular Glue Degrader Discovery Platform Proprietary, highly versatile discovery engine enabling specific and unbiased identification of molecular glue degraders against difficult-to-drug or completely undruggable targets at large scale, integrating genomic, proteomic, and biochemical technologies through a ligase-agnostic screening approach.
- MSD Partnered Programs Undisclosed molecular glue degrader programs being co-developed with MSD (Merck & Co Inc.) targeting multiple therapeutic areas under a multi-year research collaboration and license agreement.
Quantifiable outcome
- Over 80% of human proteins are not accessible via traditional drug approaches and are generally considered 'undruggable' - Proxygen's glue degraders can address these targets
- +1 more outcomes
Companies that use Proxygen
Customer profileSegments2 records
Ideal customer profiles1 record
Proxygen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Proxygen partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- EPFL (Swiss Federal Institute of Technology in Lausanne)flagshipStrategic research collaboration combining Proxygen's validated glue degrader discovery platform with EPFL's pioneering work in AI and structural modeling for protein design. Partnership aims to build next-generation discovery paradigm bridging high-throughput in vitro screening with state-of-the-art in silico design to predict and validate neosubstrate-ligase interactions and design chemical matter for targeted protein degradation.
- MSD (Merck & Co Inc.)coreMulti-year research collaboration and license agreement to jointly identify and develop molecular glue degraders against multiple therapeutic targets. Proxygen received upfront payment and is eligible for future payments of up to $2.55 billion based on achievement of specified research, development, and commercial milestones across all programs, plus royalties on net sales.
- Merck KGaAcoreStrategic multi-year research collaboration and license agreement to jointly identify and develop molecular glue degraders up to clinical candidate stage. Proxygen eligible to receive up to €495 million ($554 million) in R&D funding, upfront and success-based preclinical, clinical, regulatory, and commercial milestones, plus tiered royalties.
- Boehringer IngelheimcoreCollaboration and license agreement to enable identification of molecular glue degraders against various oncogenic targets, complementing Boehringer Ingelheim's cancer research strategy. Proxygen entitled to receive upfront payments, R&D support, milestone-gated development payments, and tiered royalties based on future commercial sales.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Proxygen competitors and assessment
Company assessmentBroad incumbents
- Amgen: Amgen is a large pharmaceutical company with internal TPD initiatives and a relevant oncology-focused dealmaker. Comparable in being a potential partner/competitor for protein degrader programs in oncology indications similar to Proxygen's lead targets.
- Novartis: Novartis is a major pharmaceutical company with active TPD programs and historical investments in protein degradation (including through collaborations and internal R&D). A potential strategic partner or acquirer for Proxygen's platform and lead programs.
- Bristol Myers Squibb: BMS is a large pharmaceutical company with significant internal TPD efforts through its Avilomics and Montelino platforms, and a major customer/partner candidate in the degrader space. Competes for similar oncology programs and partnership slots that Proxygen targets.
Emerging players
- Neomorph: Neomorph is a private biotech developing induced proximity-based molecular glues and degraders, founded by degrader pioneers. Emerging player with significant overlap to Proxygen's glue degrader discovery focus, though still at earlier stages.
- Plexium: Plexium is a private biotech developing targeted protein degraders using a proprietary DEL-Plex platform for E3 ligase ligand discovery. Comparable in scale and stage to Proxygen and addresses similar undruggable oncology targets.
- Foghorn Therapeutics: Foghorn is a clinical-stage biotech focused on chromatin biology and dysregulated gene expression, with emerging protein degrader programs. Adjacent to Proxygen's transcription-driven cancer focus (e.g., p300 program) and competes for similar oncology targets.
Direct peers
- Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and other diseases, founded by prominent TPD researchers. It is one of the closest pure-play molecular glue competitors to Proxygen and targets a similar set of undruggable oncology targets.
- Arvinas: Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders, with partnered programs (including with Pfizer) and internal oncology pipeline. It is the most established public peer in the TPD space and competes directly for both targets and pharma partnerships.
- C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing targeted protein degraders (TORPEDO platform) for oncology and other diseases, with partnerships including Roche, Biogen, and Merck KGaA's Calyx. Direct competitor in molecular glue and bifunctional degrader discovery.
- Kymera Therapeutics: Kymera is a clinical-stage biotech developing heterobifunctional degraders and molecular glue degraders across oncology and immunology, with pharma partnerships (including Sanofi). It directly competes with Proxygen in the TPD modality space and for undruggable oncology targets.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Proxygen social profiles
Digital presenceProxygen compliance and trust
Trust signalCompliance1 record
Proxygen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proxygen leadership team
Management profileNumber of profiles
Profiles4 records
Proxygen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proxygen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proxygen
What does Proxygen do?
Proxygen develops molecular glue degraders and induced proximity therapeutics using a proprietary, ligase-agnostic discovery platform that integrates genomics, proteomics, and biochemistry to systematically identify degraders against previously undruggable proteins. Its pipeline includes a first-in-class oral p300 glue degrader for transcription-driven cancers and a brain-penetrant CDK12/Cyclin K degrader for HER2-driven cancers with CNS involvement, advanced through strategic research collaborations and license agreements with global pharmaceutical companies.
Is Proxygen a public or private company?
Proxygen is a private company. It is classified as unknown and is currently operating.
When was Proxygen founded?
Proxygen was founded in 2020. It employs 51 to 100 people.
Where is Proxygen based?
Proxygen is headquartered in Vienna, Austria, in the Europe region.
How does Proxygen make money?
One revenue line is on record: pharmaceutical Partnerships and Licensing.
Who are Proxygen's main competitors?
Broad incumbents on record are Amgen, Novartis and Bristol Myers Squibb. Emerging players are Neomorph, Plexium and Foghorn Therapeutics. Direct peers are Monte Rosa Therapeutics, Arvinas, C4 Therapeutics and Kymera Therapeutics.
Does Proxygen have an API?
No public API is recorded for Proxygen.
What industry is Proxygen in?
Proxygen's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.